Lee Evelyn, Costello Michael F, Botha Willings C, Illingworth Peter, Chambers Georgina M
Centre for Social Research in Health, University of New South Wales, Sydney, New South Wales, Australia.
School of Women's and Children's Health, University of New South Wales, Sydney, New South Wales, Australia.
Aust N Z J Obstet Gynaecol. 2019 Aug;59(4):573-579. doi: 10.1111/ajo.12988. Epub 2019 May 20.
Current evidence suggests that preimplantation genetic testing for aneuploidy (PGT-A) used during assisted reproductive technology improves per-cycle live-birth rates but cumulative live-birth rate (CLBR) was similar to a strategy of morphological assessment (MA) of embryos. No study has assessed the cost-effectiveness of repeated cycles with PGT-A using longitudinal patient-level data.
To assess the cost-effectiveness of repeated cycles with PGT-A compared to MA of embryos in older women.
Micro-costing methods were used to value direct resource consumption of 2093 assisted reproductive technology-naïve women aged ≥37 years undergoing up to three 'complete assisted reproductive technology cycles' (fresh plus cryopreserved embryos) with either PGT-A or MA in an Australian clinic between 2011 and 2014. Incremental cost-effective ratios were calculated from healthcare and patient perspectives with uncertainty assessed using non-parametric bootstrap methods. Cost-effectiveness acceptability curves were constructed to evaluate the probability of PGT-A being cost-effective over a range of willingness-to-pay thresholds.
The CLBR and mean healthcare costs per patient were 30.90% and $22 962 for the PGT-A group, and 26.77% and $21 801 for the MA group, yielding an incremental cost-effective ratio of $28 103 for an additional live birth with PGT-A. At a willingness-to-pay threshold of $50 000 and above, there is more than an 80% probability of PGT-A being cost-effective from the healthcare perspective and a 50% likelihood from a patient perspective.
This is the first study to use real-world patient-level data to assess the cost-effectiveness of PGT-A in older women from the healthcare and patient perspectives. The findings contribute to the ongoing debate on the role of PGT-A in clinical practice.
目前的证据表明,辅助生殖技术中使用的非整倍体植入前基因检测(PGT-A)可提高每个周期的活产率,但累积活产率(CLBR)与胚胎形态学评估(MA)策略相似。尚无研究使用纵向患者层面数据评估重复进行PGT-A周期的成本效益。
评估老年女性中与胚胎MA相比,重复进行PGT-A周期的成本效益。
采用微观成本核算方法,对2011年至2014年期间在澳大利亚一家诊所接受PGT-A或MA治疗、年龄≥37岁、首次接受辅助生殖技术治疗的2093名女性进行评估,这些女性最多接受三个“完整辅助生殖技术周期”(新鲜胚胎加冷冻胚胎)。从医疗保健和患者角度计算增量成本效益比,并使用非参数自助法评估不确定性。构建成本效益可接受性曲线,以评估在一系列支付意愿阈值范围内PGT-A具有成本效益的概率。
PGT-A组的CLBR和每位患者的平均医疗保健成本分别为30.90%和22962美元,MA组分别为26.77%和21801美元,PGT-A多活产一例的增量成本效益比为28103美元。在支付意愿阈值为50000美元及以上时,从医疗保健角度看,PGT-A具有成本效益的概率超过80%,从患者角度看为50%。
这是第一项使用真实世界患者层面数据从医疗保健和患者角度评估PGT-A在老年女性中成本效益的研究。这些发现有助于正在进行的关于PGT-A在临床实践中作用的辩论。